US2014341849A1PendingUtilityA1

Methods and compositions related to glucocorticoid receptor antagonists and breast cancer

66
Assignee: UNIV CHICAGOPriority: Mar 24, 2010Filed: Aug 4, 2014Published: Nov 20, 2014
Est. expiryMar 24, 2030(~3.7 yrs left)· nominal 20-yr term from priority
Inventors:Deng PanMasha KocherginskySuzanne D. Conzen
A61P 35/00A61K 31/282A61N 5/00A61K 31/575A61K 31/357A61K 31/337A61K 31/4745A61K 45/06A61K 31/567A61K 31/7068A61J 1/00A61K 31/58A61K 39/3955A61K 33/243
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or compound.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A pharmaceutical composition for treating breast cancer in a patient which is characterized by expression of a glucocorticoid receptor, comprising therapeutically effective amounts of:
 a) at least one anticancer agent:   b) a glucocorticoid receptor antagonist (GRA); and,   c) optionally, a pharmaceutically acceptable formulation.   
     
     
         2 . The composition of  claim 1  wherein the anticancer compound is selected from the group consisting of capecitabine, carboplatin, cyclophosphamide (Cytoxan), daunorubicin, docetaxel (Taxotere), doxorubicin (Adriamycin), epirubicin (Ellence), fluorouracil (also called 5-fluorouracil or 5-FU), gemcitabine, eribulin, ixabepilone, methotrexate, mitomycin C, mitoxantrone, paclitaxel (Taxol), thiotepa, vincristine, or vinorelbin, or a combination of these agents. 
     
     
         3 . The composition of  claim 1  wherein the anticancer compound is a taxane derivative. 
     
     
         4 . The composition of  claim 1  wherein the anticancer compound is either placlitaxel or docetaxel. 
     
     
         5 . The composition of  claim 1  wherein the anticancer compound is Herceptin®. 
     
     
         6 . The composition of  claim 1  wherein the GRA is a steroidal compound. 
     
     
         7 . The composition of  claim 1  wherein the GRA is mifepristone. 
     
     
         8 . The composition of  claim 1  wherein the GRA is ORG 34517. 
     
     
         9 . The composition of  claim 1  wherein the GRA is a non-steroidal compound. 
     
     
         10 . The pharmaceutical composition of  claim 1 , wherein the breast cancer is chemo-resistant ER − /GR +  breast cancer. 
     
     
         11 . A pharmaceutical composition for treating breast cancer in a patient which is characterized by expression of a glucocorticoid receptor, comprising therapeutically effective amounts of:
 a) an anticancer agent selected from, taxanes wherein the taxane is paclitaxel and docetaxel, and combinations thereof;   b) a glucocorticoid receptor antagonist (GRA) selected from the group consisting of ORG 34517 and mifepristone; and,   c) optionally a pharmaceutically acceptable formulation.   
     
     
         12 . A pharmaceutical composition of  claim 11  wherein the anticancer agent is paclitaxel and the GRA is ORG 34517. 
     
     
         13 . A pharmaceutical composition of  claim 11  wherein the anticancer agent is paclitaxel and the GRA is mifepristone. 
     
     
         14 . The pharmaceutical composition of  claim 11 , wherein the breast cancer is chemo-resistant ER − /GR +  breast cancer.

Join the waitlist — get patent alerts

Track US2014341849A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.